Servier key figures
key figures
We help to drive therapeutic progress
As a global pharmaceutical Group, we help to drive therapeutic progress by investing close to 20% of revenue from brand-name medicines in R&D each year.
About Servier
35th
largest pharmaceutical group worldwide1
2nd
largest French pharmaceutical group1
20%
Close to 20% of revenue from brand-name medicines invested in R&D each year
60
Over 60 partnerships and research collaborations in 2024/2025 and a network of more than 300 academic and industrial partners worldwide
20,000
Over 20,000 employees
96.1%
of the active ingredients used in the Group’s brand-name medicines are produced by Servier in France
177
international patient organizations collaborated with Servier in 2024/2025
Driving scientific and medical progress
3
therapeutic areas: oncology, cardiometabolism & venous diseases, neurology
41
projects in clinical development (including 18 new molecular entities) and 21 research projects (January 2026)
5th
leading pharmaceutical group in cardiology worldwide1
1st
leading pharmaceutical group in hypertension worldwide1
Global presence
130
Over 130 countries where the Group’s medicines are distributed
13
production sites
6
research & development centers
19
International Centers for Therapeutic Research
Social responsibility
-42%
Reduce our GHG emissions by 42% by 2030, scope 1&2, with 2021/2022 as baseline year3
-16%
emissions of scope 1&2 have decreased by 16% in 2024/2025 compared to 2021/2022 baseline
50%
of the Group’s managers are women as of 2024/2025
4.35/5
overall engagement score achieved by the Servier Group2
Financial performance
€6.9
billion in revenue in 2024/20254
€ 1.9
billion in EBITDA4 in 2024/2025 or 28.2% of Group revenue
[1] IQVIA, Analytics Link / World 84 countries – MAT Q3-2025
[2] Source: annual engagement survey conducted with the Gallup Institute – 2025 Group results
[3] Scope 1 emissions represent emissions directly linked to Group operations. Scope 2 emissions are linked to the purchase of electricity and energy for heating or cooling
[4] The Group’s 2024/2025 financial information includes activities related to Biogaran and is compared to the published Group’s 2023/2024 financial information including activities related to Biogaran.